Sunshine Biopharma registers 25.5M shares underlying Series B Warrants; may net $31M if exercised

The prospectus cover discloses the most recent market price for the company's common stock, which is $1.27 per share as of August 27, 2026. This provides a reference point for investors evaluating the offering.

The filing notes that the terms of the Series B Warrants, including the number of underlying shares and exercise price, may change. This introduces uncertainty about the final warrant terms and potential dilution.

The prospectus registers 25,477,133 shares of common stock that may be issued if the Series B Warrants are exercised. These warrants were originally issued in a public offering that closed on February 15, 2024. The shares are not being sold by the company in this offering; they will only be issued upon warrant exercise.

The Series B Warrants have an exercise price of $1.2202 per share, which can be adjusted downward if the company issues shares at a lower price or if certain share splits or similar events occur. This anti-dilution protection could increase the number of shares issued upon exercise and dilute existing shareholders.

The company has completed three reverse stock splits since April 2024, reducing the number of outstanding shares by a combined factor of 20,000. This is often done to meet exchange listing requirements or boost the share price, but it can signal financial distress and significantly reduce shareholder ownership percentages.

The company states it could receive about $31 million in net proceeds if all outstanding Series B Warrants are exercised for cash at the current exercise price. However, there is no assurance any warrants will be exercised, so this amount is contingent and not guaranteed.

The company plans to use the net proceeds for general corporate purposes, including working capital. This is a broad statement with no specific allocation, giving management flexibility.

The company cannot specify all uses of proceeds at this time, and management will have broad discretion over timing and application. This is typical for early-stage companies but means investors have limited visibility into how funds will be spent.

The company discloses that it may be delisted from Nasdaq if it fails to meet listing requirements. This is a company-specific risk because it relates to the company's current listing status and recent reverse stock split.

The company's stock traded below the $1.00 minimum bid price before its reverse split, indicating past noncompliance. The reverse split was likely done to regain compliance, but the risk remains.

Because the company completed a reverse stock split within the past year, it faces an expedited delisting process if the stock price falls below $1.00 for 30 consecutive business days. This is a specific regulatory consequence tied to the company's recent actions.

Nasdaq proposed a new $5 million market value requirement, and the company currently does not meet it. Although the SEC's approval was stayed pending review, this creates uncertainty about the company's continued listing.

The prospectus states that M&K CPA’s, PLLC audited the company's consolidated financial statements for the year ended December 31, 2025. This is a change from the prior year's auditor, Bush & Associates CPA LLC, which audited the 2024 financial statements.

The prospectus states that Bush & Associates CPA LLC audited the company's consolidated financial statements for the year ended December 31, 2024. This is the prior auditor, and the change to M&K CPA’s, PLLC for 2025 may be of interest to investors.